Liquidia Corporation

Pulmonary arterial hypertension (#PAH) is a rare, chronic, progressive disease caused by hardening and narrowing of the pulmonary arteries that can lead to heart right failure and eventually death. Its estimated treated prevalence in the United States is approximately 40,000 patients. Interested in learning more about PAH? Check out the Pulmonary Hypertension Association website at https://bit.ly/3KZupvi.

“Since 1973, the World Symposia on Pulmonary Hypertension has contributed to the ongoing scientific advancement of our field. We are delighted to present seven thematic posters on the world stage showcasing YUTREPIA and L606. We look forward to initiating a global, pivotal placebo-controlled efficacy trial of L606 in PH-ILD later this year." – Rajeev Saggar, Chief Medical Officer, Liquidia Click here to view our press release and learn more about our posters: https://bit.ly/3VJXDEG #WSPH2024

“Since 1973, the World Symposia on Pulmonary Hypertension has contributed to the ongoing scientific advancement of our field. We are delighted to present seven thematic posters on the world stage showcasing YUTREPIA and L606. We look forward to initiating a global, pivotal placebo-controlled efficacy trial of L606 in PH-ILD later this year." – Rajeev Saggar, Chief Medical Officer, Liquidia Click here to view our press release and learn more about our posters: https://bit.ly/3VJXDEG #WSPH2024

Last week, we celebrated Liquidia’s 20-year anniversary by reflecting on the past, present and bright future we’re aiming to deliver to physicians and patients with PAH and PH-ILD. We kicked things off with a stellar team photo featuring many of our NC-based teammates and a few guests from around the country, followed by an Employee Appreciation event including a special nod to the many new and tenured teammates who make our company such a phenomenal place to work. Here’s to 20 more years of commitment to the discovery, engineering, and development required to bring novel therapies to patients who need them most and the healthcare providers who care for them. #liquidia #lifesciences #biopharma #northcarolina

Last week, we celebrated Liquidia’s 20-year anniversary by reflecting on the past, present and bright future we’re aiming to deliver to physicians and patients with PAH and PH-ILD. We kicked things off with a stellar team photo featuring many of our NC-based teammates and a few guests from around the country, followed by an Employee Appreciation event including a special nod to the many new and tenured teammates who make our company such a phenomenal place to work. Here’s to 20 more years of commitment to the discovery, engineering, and development required to bring novel therapies to patients who need them most and the healthcare providers who care for them. #liquidia #lifesciences #biopharma #northcarolina

As we inch ever closer to summer, we’re proud of the productive spring we’ve had at Liquidia.   In May, we unveiled our largest booth to date at the American Thoracic Society International Conference (#ATS2024) meeting in San Diego, CA where we were delighted to meet with physicians, patient advocacy groups and other industry KOLs to learn more about the issues they deem most important, and to share insights about our company. It's certainly an exciting time to be part of Liquida!    #liquidia #lifesciences #biopharma #northcarolina

Press Release: District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch https://lnkd.in/gcszGdaU

Press Release: District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch https://lnkd.in/gcszGdaU

As we inch ever closer to summer, we’re proud of the productive spring we’ve had at Liquidia.   In May, we unveiled our largest booth to date at the American Thoracic Society International Conference (#ATS2024) meeting in San Diego, CA where we were delighted to meet with physicians, patient advocacy groups and other industry KOLs to learn more about the issues they deem most important, and to share insights about our company. It's certainly an exciting time to be part of Liquida!    #liquidia #lifesciences #biopharma #northcarolina

As we inch ever closer to summer, we’re proud of the productive spring we’ve had at Liquidia.   In May, we unveiled our largest booth to date at the American Thoracic Society International Conference (#ATS2024) meeting in San Diego, CA where we were delighted to meet with physicians, patient advocacy groups and other industry KOLs to learn more about the issues they deem most important, and to share insights about our company. It's certainly an exciting time to be part of Liquida!    #liquidia #lifesciences #biopharma #northcarolina